Faron Pharmaceuticals
Ltd.
("Faron"
or "the Company")
Faron's Financial Calendar
for 2025
Company announcement, 13 December 2024
TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First
North: FARON), a clinical-stage biopharmaceutical company focused
on tackling cancers via novel immunotherapies, today announces the following dates for the Company's
financial reporting in 2025:
|
February 27
|
Financial statement release for the
full year 2024 and Annual Report 2024 including financial
statements for the full year
|
|
August 27
|
Half-year financial report for the
period January 1 to June 30, 2025
|
The Annual General Meeting is
planned to be held on March 21, 2025. A separate stock exchange notice
will be issued by Faron's Board of Directors to convene the
meeting.
For
more information please contact:
ICR
Healthcare
Mary-Jane Elliott,
David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@icrhealthcare.com
Cairn
Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel
Hunt LLP, Broker
Christopher Golden, James
Steel
Phone: +44 (0) 20 7418 8900
Sisu
Partners Oy, Certified Adviser on Nasdaq First
North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553
8990
About
Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON)
is a global, clinical-stage biopharmaceutical company, focused on
tackling cancers via novel immunotherapies. Its mission is to bring
the promise of immunotherapy to a broader population by uncovering
novel ways to control and harness the power of the immune system.
The Company's lead asset is bexmarilimab, a novel anti-Clever-1
humanized antibody, with the potential to remove immunosuppression
of cancers through reprogramming myeloid cell
function. Bexmarilimab is being
investigated in Phase I/II clinical trials as a potential therapy
for patients with hematological cancers in combination with other
standard treatments. Further information is available
at www.faron.com.